Lv1
53 积分 2020-10-23 加入
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
4天前
已完结
A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement
8天前
已完结
Beyond cytotoxic potency: disposition features required to design ADC payload
17天前
已完结
State-Dependent Inhibition of Nav1.8 Sodium Channels by VX-150 and VX-548
1个月前
已完结
US drug agency approves potent painkiller — the first non-opioid in decades
1个月前
已完结
Outlook for medicines development and use in 2025
2个月前
已完结
Biopharma deals get smaller and earlier
2个月前
已完结
Discovery and Characterization of a Bicyclic Peptide (Bicycle) Binder to Thymic Stromal Lymphopoietin
2个月前
已完结
Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors
3个月前
已完结
NaV1.8 inhibitor poised to provide opioid-free pain relief
3个月前
已完结
皖公网安备34019202002308
